Beijing Shijitan Hospital

Running trials

• Recruiting

  A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants

  NCT07784699· Phase 1· Gan & Lee Pharmaceuticals.· Source

• Recruiting

  Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring

  NCT07747701· Beijing Shijitan Hospital, Capital Medical University· Source

• Recruiting

  Early Identification and Diagnosis of BAD-related Stroke

  NCT07693816· Peking Union Medical College Hospital· Source

• Recruiting

  Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation

  NCT07556068· Beijing Shijitan Hospital, Capital Medical University· Source

• Recruiting

  A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

  NCT07189065· Phase 2· Guangzhou Lupeng Pharmaceutical Company LTD.· Source

• Recruiting

  Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

  NCT07205432· Phase 1· Shanghai Xitaili Biomedicine Technology co., Ltd.· Source

• Not yet recruiting

  Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke

  NCT06374823· Phase 4· Capital Medical University· Source

• Active, not recruiting

  A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT05388669· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

  NCT04995159· Lepu Medical Technology (Beijing) Co., Ltd.· Source

• Enrolling by invitation

  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

  NCT03683186· Phase 3· United Therapeutics· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke4 recruiting
• Obesity2 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• High blood pressure1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke

  NCT06485427· Beijing Shijitan Hospital, Capital Medical University· Source

• Completed

  Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

  NCT06037889· Phase 3· Peking Union Medical College Hospital· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Actelion· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  Prospective, Observational, Real-world Oral Malignant Tumors Study

  NCT02395367· Beijing Stomatological Hospital, Capital Medical University· Source

Trial sites

• Beijing Shijitan Hospital5 trials
• Beijing Shijitan Hospital, Capital Medical University10 trials
• Department of Radiation Oncology, Beijing Shijitan Hospital, Capital Medical University1 trial